0.9% sodium chloride - inhalation solution

DRUG2 trials

Sponsors

Arrowhead Pharmaceuticals Inc.

Conditions

Asthma and Chronic obstructive pulmonary diseaseInflammatory Lung Disease

Phase 1

A Phase 1/2a Study Evaluating the Effects of ARO-RAGE Inhalation Solution in Healthy Subjects and Patients with Inflammatory Lung Disease

CompletedCTIS2023-509654-60-00

Arrowhead Pharmaceuticals Inc.Inflammatory Lung Disease

Start: 2023-06-21End: 2025-04-16Target: 42Updated: 2024-12-12

A Phase 1/2a Study Evaluating the Effects of ARO-MUC5AC Inhalation Solution in Healthy Subjects and Patients with Muco-Obstructive Lung Disease

CompletedCTIS2024-514809-67-00

Arrowhead Pharmaceuticals Inc.Asthma and Chronic obstructive pulmonary disease

Start: 2023-06-21End: 2024-10-24Target: 32Updated: 2024-10-01